Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management—Second...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management—Second Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 20 July 2026 | Viewed by 2255

Special Issue Editor

Dr. Pablo Demelo-Rodríguez

E-Mail Website
Guest Editor
Venous Thromboembolism Unit, Internal Medicine, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
Interests: internal medicine; deep vein thrombosis; pulmonary embolism; cerebral venous thrombosis; venous thromboembolism; anticoagulation therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following on from the success of our first Special Issue, entitled “Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management”  (https://www.mdpi.com/si/jcm/7P3VQ26CIH), we are launching a new Special Issue, entitled “Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management—Second Edition”, which continues to report on clinical research.

Deep vein thrombosis (DVT) and pulmonary embolism (PE) continue to be significant medical challenges with increasing implications in terms of hospitalizations and morbidity. These conditions affect a substantial number of patients worldwide, and their consequences can be devastating if they are not adequately addressed. Thus, our Special Issue focuses on providing updated and comprehensive insights into the clinical management and treatment of DVT and PE.

We invite contributions that address a wide range of topics, including the management of DVT, the use of systemic thrombolytic therapies, catheter-directed pulmonary reperfusion, mechanical thrombectomy for DVT, surgical embolectomy, and extracorporeal embolectomy. We also explore bleeding risk assessments and management, right ventricular function, the outpatient treatment of low-risk PE and/or DVT, and long-term management, which includes anticoagulation, screening, and the treatment of complications. Furthermore, we delve into the relationship between venous thrombosis and cancer, as well as the complications associated with COVID-19-related venous thrombosis.

This Special Issue represents a compendium of cutting-edge research and reviews that will provide clinicians with a solid foundation to enhance our understanding of DVT and PE and improve patient care.

We eagerly await your contributions!

Dr. Pablo Demelo-Rodríguez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary embolism
  • thrombophilia
  • deep vein thrombosis
  • venous thromboembolism
  • anticoagulation therapy
  • thrombectomy
  • bleeding
  • cancer-associated thrombosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 230 KB  
Article
Impact of Endovascular Treatment on the Development of Post-Thrombotic Syndrome in Iliac and Iliofemoral Deep Vein Thrombosis
by Gabriel Puche Palao, Javier Trujillo-Santos, Sonia Otálora, Leticia Guirado-Torrecillas, Javier Pagán-Escribano and Pablo Demelo-Rodríguez
J. Clin. Med. 2025, 14(17), 6280; https://doi.org/10.3390/jcm14176280 - 5 Sep 2025
Cited by 1 | Viewed by 1295
Abstract
Background: Post-thrombotic syndrome (PTS) is a frequent complication of deep vein thrombosis (DVT), with significant clinical and quality-of-life implications. Endovascular techniques have emerged as potential strategies to reduce PTS severity in selected patients, though evidence remains inconclusive. Methods: We conducted a multicenter, retrospective [...] Read more.
Background: Post-thrombotic syndrome (PTS) is a frequent complication of deep vein thrombosis (DVT), with significant clinical and quality-of-life implications. Endovascular techniques have emerged as potential strategies to reduce PTS severity in selected patients, though evidence remains inconclusive. Methods: We conducted a multicenter, retrospective study including 176 patients with iliac or iliofemoral DVT from four hospitals in Murcia, Spain. Patients were treated either with anticoagulation alone (n = 121) or with endovascular techniques followed by anticoagulation (n = 55). The primary outcome was the presence of PTS at 12 months, defined by the presence of ≥5 signs/symptoms from the Villalta scale. Multivariate analysis was performed to identify independent predictors of PTS. Results: No significant differences were observed in the overall prevalence of PTS between the endovascular and anticoagulation-only groups at 12 months (25.4% vs. 23.2%, p = 0.63). However, edema and skin hyperpigmentation were significantly more frequent in the anticoagulation-only group. Patients treated with endovascular techniques had lower rates of residual thrombosis at follow-up (34.6% vs. 53.9%, p = 0.03). Multivariate analysis identified residual thrombosis (OR 6.3, 95% CI 2.74–14.5), persistently elevated D-dimer (OR 3.26, 95% CI 1.1–9.7), and age (OR 1.02, 95% CI 1.003–1.042) as independent predictors of PTS. Mortality was significantly higher in the anticoagulation-only group, largely driven by a higher cancer prevalence. Conclusions: Endovascular techniques did not significantly reduce the overall incidence of PTS but were associated with lower rates of specific signs such as edema and hyperpigmentation. Residual thrombosis remains a key predictor of PTS and may represent a modifiable therapeutic target. Full article
(This article belongs to the Special Issue Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management—Second Edition)

Other

Jump to: Research

14 pages, 1324 KB  
Systematic Review
Safety and Efficacy of Direct Oral Anticoagulants Versus Standard Therapy for Venous Thromboembolism in Cancer Patients: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
by Alaa Shahbar, Sabah Alshahrani, Abdullah Alhifany, Mohammed Alnuhait, Afnan Noor, Abdulaali Almutairi, Faisal A. Alhamdan, Ahmad A. Alshamrani and Alqassem Y. Hakami
J. Clin. Med. 2026, 15(3), 1090; https://doi.org/10.3390/jcm15031090 - 30 Jan 2026
Viewed by 640
Abstract
Background: Patients with malignancy demonstrate an elevated risk of developing venous thromboembolism (VTE) due to coagulopathy and treatment modalities. Although low-molecular-weight heparin (LMWH) and warfarin have historically been standard therapies, direct oral anticoagulants (DOACs) are increasingly used in this population. Methods: [...] Read more.
Background: Patients with malignancy demonstrate an elevated risk of developing venous thromboembolism (VTE) due to coagulopathy and treatment modalities. Although low-molecular-weight heparin (LMWH) and warfarin have historically been standard therapies, direct oral anticoagulants (DOACs) are increasingly used in this population. Methods: We conducted a Bayesian network meta-analysis to compare the safety and efficacy of apixaban, edoxaban, rivaroxaban, LMWH, and warfarin in cancer-associated VTE. A comprehensive literature search of Embase, Medline, clinical trial registries, and manual sources was performed up to November 2025. The primary outcome was to compare the risk of VTE recurrence across therapies. Secondary outcomes included major bleeding, clinically relevant non-major bleeding (CRNMB), and all-cause mortality. Odds ratios (ORs) with 95% credible intervals (CrIs) were estimated, and treatment rankings were derived using the surface under the cumulative ranking curves (SUCRA) probabilities. Results: Seven randomized controlled trials (RCTs) involving 3325 patients were included. No clear evidence of differences was observed among apixaban, rivaroxaban, edoxaban, low-molecular-weight heparin, and warfarin for VTE recurrence, major bleeding, clinically relevant non-major bleeding, and mortality. For instance, rivaroxaban showed no statistically significant difference in VTE recurrence compared with apixaban (OR 1.13; 95% CrI 0.17–12.27), warfarin (OR 0.60; 95% CrI 0.03–19.00), edoxaban (OR 0.77; 95% CrI 0.06–11.11), or LMWH (OR 0.51; 95% CrI 0.10–2.66). Wide credible intervals reflect uncertainty due to the limited number of RCTs and low event rates. Conclusions: This Bayesian network meta-analysis showed no statistically significant differences between therapies with respect to VTE recurrence, bleeding outcomes, and mortality. However, the wide credible intervals indicate limited precision, warranting cautious interpretation of the findings. Full article
(This article belongs to the Special Issue Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management—Second Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop